GNTA logo

GENENTA SCIENCE SPA - ADR

GNTANASDAQ
🏆 #4440 by market capEarnings Mar 3US Equity
$0.61▼ $0.01 (−2.14%)
🌅 Pre-market$0.60▼ 0.83%Regular close · extended-hours price shown
🔔
Track GNTA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.1%
7d▼ 4.0%
14d▼ 11.1%
30d▼ 10.9%
ytd▼ 57.7%
1y▼ 80.2%
🏦Market Cap
$14M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.58 – $0.63
52-Week Range
—
Volume (shares)
41,992
Avg Volume (shares)
—
Shares Outstanding
23.6M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+16.0%
GNTA logo

GENENTA SCIENCE SPA - ADR

GNTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −37.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▲ +10.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.2M▲ +16.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$2M▼ −$7M YoY
StockOtter · stockotter.space

About GENENTA SCIENCE SPA - ADR

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

GlobeNewsWire·7d ago

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department

GlobeNewsWire·Sep 15

Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit

The Spring Assembly manufactured by Sòphia HT, a strategic Genenta investment, supports the separation of the launcher's second and third stages Sòphia HT has been in serial production of the component since 2018 MILAN,